Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20


FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P.

Cytokine. 2019 Aug;120:85-87. doi: 10.1016/j.cyto.2019.04.015. Epub 2019 Apr 28.


CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.

Papin A, Tessoulin B, Bellanger C, Moreau A, Le Bris Y, Maisonneuve H, Moreau P, Touzeau C, Amiot M, Pellat-Deceunynck C, Le Gouill S, Chiron D.

Leukemia. 2019 Apr 2. doi: 10.1038/s41375-019-0463-3. [Epub ahead of print]


Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies.

Bouard L, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Duquenne A, Mahe B, Dubruille V, Blin N, Touzeau C, Gastinne T, Le Bris Y, Lok A, Bonnet A, Le Gouill S, Moreau P, Bene MC, Chevallier P.

Biol Blood Marrow Transplant. 2019 Mar 27. pii: S1083-8791(19)30209-5. doi: 10.1016/j.bbmt.2019.03.025. [Epub ahead of print]


FLT3 ligand plasma levels in acute myeloid leukemia.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P.

Haematologica. 2019 Jun;104(6):e240-e243. doi: 10.3324/haematol.2018.209460. Epub 2019 Jan 10. No abstract available.


p53 regulates CD46 expression and measles virus infection in myeloma cells.

Lok A, Descamps G, Tessoulin B, Chiron D, Eveillard M, Godon C, Le Bris Y, Vabret A, Bellanger C, Maillet L, Barillé-Nion S, Gregoire M, Fonteneau JF, Le Gouill S, Moreau P, Tangy F, Amiot M, Moreau-Aubry A, Pellat-Deceunynck C.

Blood Adv. 2018 Dec 11;2(23):3492-3505. doi: 10.1182/bloodadvances.2018025106.


A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patients.

Boutault R, Peterlin P, Boubaya M, Sockel K, Chevallier P, Garnier A, Guillaume T, Le Bourgeois A, Debord C, Godon C, Le Bris Y, Theisen O, Kroschinsky F, Moreau P, Béné MC, Platzbecker U, Eveillard M.

Br J Haematol. 2018 Dec;183(5):736-746. doi: 10.1111/bjh.15626. Epub 2018 Nov 8.


Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies.

Chevallier P, Peterlin P, Garnier A, Le Bourgeois A, Mahé B, Dubruille V, Blin N, Touzeau C, Gastinne T, Lok A, Le Bris Y, Béné MC, Le Gouill S, Moreau P, Guillaume T.

Oncotarget. 2018 Sep 11;9(71):33528-33535. doi: 10.18632/oncotarget.26083. eCollection 2018 Sep 11.


Rituximab for second desensitization in patients with rebound of donor-specific anti-HLA antibodies before T-replete haplo-transplant using high-dose post-transplant cyclophosphamide.

Garnier A, Delbos F, Guillaume T, Peterlin P, Le Bourgeois A, Béné MC, Le Bris Y, Malard S, Duquesne A, Gauvrit I, Moreau P, Cesbron A, Chevallier P.

Bone Marrow Transplant. 2018 Aug;53(8):1044-1047. doi: 10.1038/s41409-018-0107-7. Epub 2018 Feb 1. No abstract available.


Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide.

Lodé L, Ménard A, Flet L, Richebourg S, Loirat M, Eveillard M, Le Bris Y, Godon C, Theisen O, Gagez AL, Cartron G, Commes-Maerten T, Villemagne B, Luycx O, Godmer P, Pellat-Deceunynck C, Soussi T, Béné MC, Delaunay J, Peterlin P.

Haematologica. 2018 Apr;103(4):e143-e146. doi: 10.3324/haematol.2017.181404. Epub 2017 Dec 21. No abstract available.


Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study.

Mansier O, Luque Paz D, Ianotto JC, Le Bris Y, Chauveau A, Boyer F, Conejero C, Fitoussi O, Riou J, Adiko D, Touati M, Chauzeix J, Viallard JF, Béné MC, Giraudier S, Ugo V, Lippert E.

Am J Hematol. 2018 Aug;93(4):E84-E86. doi: 10.1002/ajh.25014. Epub 2018 Jan 12. No abstract available.


Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations.

Lodé L, Ameur A, Coste T, Ménard A, Richebourg S, Gaillard JB, Le Bris Y, Béné MC, Lavabre-Bertrand T, Soussi T.

Haematologica. 2018 Jan;103(1):e13-e16. doi: 10.3324/haematol.2017.176719. Epub 2017 Oct 27. No abstract available.


Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?

Lestang E, Peterlin P, Le Bris Y, Dubruille V, Delaunay J, Godon C, Theisen O, Blin N, Mahe B, Gastinne T, Garnier A, Touzeau C, Voldoire M, Bene MC, Le Gouill S, Milpied N, Mohty M, Moreau P, Guillaume T, Chevallier P.

Eur J Haematol. 2017 Jul;99(1):60-69. doi: 10.1111/ejh.12891. Epub 2017 May 5.


Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier.

Garnier A, Guillaume T, Peterlin P, Béné MC, Le Bris Y, Dubruille V, Mahé B, Gastinne T, Touzeau C, Blin N, Le Gouill S, Moreau P, Chevallier P.

Bone Marrow Transplant. 2017 Jul;52(7):1063-1064. doi: 10.1038/bmt.2017.60. Epub 2017 Apr 3. No abstract available.


Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults.

Le Bris Y, Guillaume T, Ménard A, Illiaquer M, Martin J, Malard S, Duquesne A, Peterlin P, Debord C, Robillard N, Eveillard M, Wuillème S, Delaunay J, Mohty M, Garnier A, Moreau P, Béné MC, Chevallier P.

Bone Marrow Transplant. 2017 Jun;52(6):854-858. doi: 10.1038/bmt.2016.364. Epub 2017 Jan 30.


Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.

Le Bris Y, Struski S, Guièze R, Rouvellat C, Prade N, Troussard X, Tournilhac O, Béné MC, Delabesse E, Ysebaert L.

Hematol Oncol. 2017 Dec;35(4):664-670. doi: 10.1002/hon.2349. Epub 2016 Sep 28.


Longer delay of hematological recovery and increased transfusion needs after haploidentical compared to non-haploidentical stem cell transplantation.

Desjonqueres A, Illiaquer M, Duquesne A, Le Bris Y, Peterlin P, Guillaume T, Delaunay J, Rialland F, Moreau P, Béné MC, Chevallier P, Eveillard M.

Bone Marrow Transplant. 2016 Aug;51(8):1150-2. doi: 10.1038/bmt.2016.80. Epub 2016 Apr 4. No abstract available.


Flow cytometry in hematological nonmalignant disorders.

Béné MC, Le Bris Y, Robillard N, Wuillème S, Fouassier M, Eveillard M.

Int J Lab Hematol. 2016 Feb;38(1):5-16. doi: 10.1111/ijlh.12438. Epub 2015 Nov 6. Review.


Misleading acute promyelocytic leukemia morphology.

Wuillème S, Le Bris Y.

Blood. 2015 Jun 11;125(24):3815. No abstract available.


Pan-European distribution of white-nose syndrome fungus (Geomyces destructans) not associated with mass mortality.

Puechmaille SJ, Wibbelt G, Korn V, Fuller H, Forget F, Mühldorfer K, Kurth A, Bogdanowicz W, Borel C, Bosch T, Cherezy T, Drebet M, Görföl T, Haarsma AJ, Herhaus F, Hallart G, Hammer M, Jungmann C, Le Bris Y, Lutsar L, Masing M, Mulkens B, Passior K, Starrach M, Wojtaszewski A, Zöphel U, Teeling EC.

PLoS One. 2011 Apr 27;6(4):e19167. doi: 10.1371/journal.pone.0019167.


Efficient characterization of the TCR repertoire in lymph nodes by flow cytometry.

Salameire D, Le Bris Y, Fabre B, Fauconnier J, Solly F, Pernollet M, Bonnefoix T, Leroux D, Plumas J, Jacob MC.

Cytometry A. 2009 Sep;75(9):743-51. doi: 10.1002/cyto.a.20767.

Supplemental Content

Loading ...
Support Center